FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | D.C. | 20549 |
|-------------|------|-------|
|-------------|------|-------|

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPE | ROVAL | | | | |
|----------------------|-----------|--|--|--|--|
| OMB Number: | 3235-0287 | | | | |
| Estimated average bu | urden | | | | |
| hours per response: | 0.5 | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | | - () | | | | | | | | | | | | | | | |
|---|---|--|---|-------------------------------|--|---|---|-------|--------------|--------------------------------|--|---------------------|---|---------------|--------------------------------------|--|--|---|--|--|--|--|
| Name and Address of Reporting Person* Moat Ross | | | | | 2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals, Ltd. [KNSA] | | | | | | | | | Chec | k all appli Directo | tionship of Reporting Person all applicable) Director Officer (give title | | | n(s) to Issuer 10% Owner Other (specify | | | |
| | IIKSA PHA | irst) ARMACEUTICA USE 2 CHURCE | | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/15/2021 | | | | | | | | | | X | below) | | below) | эреспу | | |
| (Street) HAMILT | | | HM11 (Zip) | | 4. If | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | | | . Indi ine) X | • | | | | | |
| | | Tab | le I - No | n-Deriv | ative | Sec | uritie | es Ac | qu | ıired, | Dis | posed (| of, d | or Ber | nefici | ally | Owned | ŀ | | | | |
| Dat | | | | 2. Transa Date (Month/D | | Ex r) if a | 2A. Deemed Execution Date, if any (Month/Day/Year) | | Code (Instr. | | 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5) | | | | 4 and Securit Benefic Owned | | es ally Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | | | Code | v | Amount | | (A) or (D) | Price | ! | Reporte Transac (Instr. 3 | tion(s) | | | (Instr. 4) | |
| Class A Common Share | | | | 07/15 | /2021 | 2021 | | | | A ⁽¹⁾ | | 963 | | A | \$11 | .49 | 4, | 4,345 | | D | | |
| Class A Common Share 0: | | | | 01/15 | /2022 | 2022 | | | | A ⁽²⁾ | | 1,546 | | A | \$9. | 63 | 5,891 | | D | | | |
| Class A Common Share 03/16/ | | | | | /2022 |)22 | | | M | | 995 | | A | (3) | | 6,886 | | D | | | | |
| Class A Common Share 03/16/ | | | | | 2022 | | | F | | 544 | | D | \$10 | 310.13 | | 6,342 | | D | | | | |
| | | Т | able II - | | | | | | • | | • | osed of converti | • | | | - | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deeme Execution if any (Month/Da | n Date, | 4. Transac Code (li 8) | | 5. Number of | | Ex | Date Ex piration onth/Da | Date | | 7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4) | | | Di Si | . Price of erivative ecurity nstr. 5) | 9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4) | Own Forn Dire or In (I) (II | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | Code | v | (A) | (D) | Da Ex | ite ercisab | | expiration Date | Title | | Amoun or Numbe of Shares | er | | | | | | |
| Restricted Share Unit | (3) | 03/16/2022 | | | М | | | 995 | | (4) | | (4) | | ass A nmon | 995 | | \$0 | 2,982 | | D | | |

Explanation of Responses:

- 1. The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2021 to July 15, 2021. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
- 2. The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2021 to January 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).
- 3. Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.
- 4. The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021.

/s/ Madelyn Zeylikman, 03/18/2022 Attorney-in-Fact for Ross Moat

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.